Welcome to our dedicated page for Dyne Therapeutics news (Ticker: DYN), a resource for investors and traders seeking the latest updates and insights on Dyne Therapeutics stock.
Dyne Therapeutics, Inc. develops investigational therapies for genetically driven neuromuscular diseases using its FORCE platform, which is designed to deliver payloads to muscle tissue and the central nervous system. Company news centers on clinical programs in Duchenne muscular dystrophy and myotonic dystrophy type 1, including z-rostudirsen, z-basivarsen, the DELIVER, ACHIEVE and HARMONIA studies, and preclinical work in additional neuromuscular diseases.
Recurring updates include clinical data presentations, FDA interactions and designations, financial results, cash-resource commentary, medical-conference abstracts, access-related research, investor conference participation and Nasdaq inducement equity grants.
Dyne Therapeutics (DYN) announced that CEO Joshua Brumm and CSO Romesh Subramanian will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 10:00 a.m. ET. The presentation will focus on the company's dedication to developing innovative therapeutics for genetically driven muscle diseases using its proprietary FORCE™ platform.
A live webcast will be accessible on the company's Investors & Media website, with a replay available for 90 days post-presentation.
Dyne Therapeutics (Nasdaq: DYN) announced its participation in several upcoming virtual investor conferences. CEO Joshua Brumm and Chief Scientific Officer Romesh Subramanian will host fireside chats at these events:
- Stifel 2020 Virtual Healthcare Conference on Nov 16, 2020, at 10:00 a.m. ET
- Jefferies Virtual London Healthcare Conference on Nov 19, 2020, at 7:55 a.m. ET
- Piper Sandler 32nd Annual Virtual Healthcare Conference, available on Nov 23, 2020
Webcast recordings will be accessible on Dyne's website for 90 days following each presentation.
Dyne Therapeutics, Inc. (Nasdaq: DYN) reported third quarter 2020 financial results, highlighting a $268 million IPO and $116 million Series B financing to fund its myotonic dystrophy type 1 and Duchenne muscular dystrophy programs. Cash and cash equivalents rose to $379.6 million from $14.6 million at year-end 2019. R&D expenses were $9.7 million, up from $3.0 million in Q3 2019. Despite a net loss of $13.9 million, the company is on track for IND submissions by late 2021 to late 2022, aiming for proof-of-concept data in its lead programs.
Dyne Therapeutics, Inc. (Nasdaq: DYN) has successfully closed its initial public offering, selling 14,089,314 shares at $19.00 per share, raising approximately $268 million in gross proceeds. This includes 1,837,736 shares from underwriters exercising their option to purchase additional shares. The stock began trading on the Nasdaq Global Select Market on September 17, 2020. J.P. Morgan, Jefferies, Piper Sandler, and Stifel acted as joint book-running managers for the offering.
Dyne Therapeutics (Nasdaq: DYN) has priced its initial public offering (IPO) of 12,251,578 shares at $19.00 each, aiming for gross proceeds of approximately $233 million before expenses. The IPO is set to begin trading on the Nasdaq Global Select Market on September 17, 2020, with the offering expected to close on September 21, 2020. The underwriters have an option to purchase an additional 1,837,736 shares within 30 days. J.P. Morgan, Jefferies, Piper Sandler, and Stifel are serving as joint book-running managers for the offering.